ALK-FISH borderline cases in non-small cell lung cancer: Implications for diagnostics and clinical decision making

Lung Cancer

Volumn 90, Issue 3, 2015, Pages 465-471

  von Laffert, Maximilian ^a   Stenzinger, Albrecht ^b   Hummel, Michael ^a   Weichert, Wilko ^b   Lenze, Dido ^a   Warth, Arne ^b   Penzel, Roland ^b   Herbst, Hermann ^c   Kellner, Udo ^d   Jurmeister, Philipp ^a   Schirmacher, Peter ^b   Dietel, Manfred ^a   Klauschen, Frederick ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^d KLINIKUM MINDEN   (Germany)

Author keywords

Anaplastic lymphoma kinase (ALK); Fluorescence in situ hybridization (FISH); Immunohistochemistry (IHC); Non small cell lung cancer (NSCLC); Statistical analysis

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ADENOSQUAMOUS CARCINOMA; ARTICLE; CANCER DIAGNOSIS; CLINICAL DECISION MAKING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; TUMOR CELL; CARCINOMA, NON-SMALL-CELL LUNG; GENE TRANSLOCATION; GENETICS; LUNG NEOPLASMS; METABOLISM; REPRODUCIBILITY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL DECISION-MAKING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; TRANSLOCATION, GENETIC;

EID: 84949184917     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2015.09.022     Document Type: Article

References (40)

1. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
2. Solomon B., Varella-Garcia M., Camidge D.R. ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer. J. Thorac. Oncol. 2009, 4:1450-1454.
3. Yoshida A., Tsuta K., Nakamura H., Kohno T., Takahashi F., et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am. J. Surg. Pathol. 2011, 35:1226-1234.
4. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin. Cancer Res. 2008, 14:4275-4283.
5. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011, 12:1004-1012.
6. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010, 363:1693-1703.
7. Weickhardt A.J., Aisner D.L., Franklin W.A., Varella-Garcia M., Doebele R.C., et al. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013, 119:1467-1477.
8. Thunnissen E., Bubendorf L., Dietel M., Elmberger G., Kerr K., et al. Consensus statement on testing for EML4-ALK in non-small-cell carcinomas of the lung. Virchows Arch. 2012, 461:245-257.
9. http://www.abbottmolecular.com/static/cms_workspace/pdfs/US/Vysis_ALK_FISH_Probe_Kit_PI.pdf.
10. Wong D.W., Leung E.L., So K.K., Tam I.Y., Sihoe A.D., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 2009, 115:1723-1733.
11. Sasaki T., Rodig S.J., Chirieac L.R., Jänne P.A. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur. J. Cancer 2010, 46:1773-1780.
12. Yoshida A., Tsuta K., Nitta H., Hatanaka Y., Asamura H., et al. Bright-field dual-color chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J. Thorac. Oncol. 2011, 6:1677-1686.
13. McLeer-Florin A., Moro-Sibilot D., Melis A., Salameire D., Lefebvre C., et al. Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a French study. J. Thorac. Oncol. 2012, 7:348-354.
14. Yi E.S., Boland J.M., Maleszewski J.J., Roden A.C., Oliveira A.M., et al. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. J. Thorac. Oncol. 2011, 6:459-465.
15. Camidge D.R., Kono S.A., Flacco A., Tan A.C., Doebele R.C., et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clin. Cancer Res. 2010, 16:581-590.
16. Camidge D.R., Theodoro M., Maxson D.A., Skokan M., O'Brien T., et al. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive non-small cell lung cancer. Cancer 2012, 118:4486-4494.
17. McLeer-Florin A., Lantuéjoul S. Why technical aspects rather than biology explain cellular heterogeneity in ALK-positive non-small cell lung cancer. J. Thorac. Dis. 2012, 4:240-241.
18. Camidge D.R., Skokan M., Kiatsimkul P., et al. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: implications for ALK inhibitor therapy. Cancer 2013, 119:3968-3975.
19. von Laffert M., Warth A., Penzel R., Schirmacher P., Jonigk D., et al. Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing. Lung Cancer 2013, 81:200-206.
20. von Laffert M., Warth A., Penzel R., Schirmacher P., Kerr K.M., et al. Multicenter immunohistochemical ALK-Testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria. J. Thorac. Oncol. 2014, 9:1685-1692.
21. Jurmeister P., Lenze D., Berg E., Mende S., Schäper F., et al. Parallel screening for ALK, MET and ROS1 alterations in non-small cell lung cancer with implications for daily routine testing. Lung Cancer 2014, 87:122-129.
22. Nitta H., Tsuta K., Yoshida A., Ho S.N., Kelly B.D., et al. New methods for ALK status diagnosis in non-small-cell lung cancer: an improved ALK immunohistochemical assay and a new Brightfield, dual ALK IHC-in situ hybridization assay. J. Thorac. Oncol. 2013, 8:1019-1031.
23. Salido M., Pijuan L., Martínez-Avilés L., Galván A.B., Cañadas I., et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J. Thorac. Oncol. 2011, 6:21-27.
24. von Laffert M., Penzel R., Schirmacher P., Warth A., Lenze D., et al. Multicenter ALK testing in non-small-cell lung cancer: results of a round robin test. J. Thorac. Oncol. 2014, 9:1464-1469.
25. Zwaenepoel K., Merkle D., Cabillic F., Berg E., Belaud-Rotureau M.A., et al. Automation of ALK gene rearrangement testing with fluorescence in situ hybridization (FISH): a feasibility study. Exp. Mol. Pathol. 2015, 98:113-118.
26. Camidge D.R., Hirsch F.R., Varella-Garcia M., Franklin W.A. Finding ALK-positive lung cancer: what are we really looking for?. J. Thorac. Oncol. 2011, 6:411-413.
27. Sozzi G., Martelli M.P., Conte D., Modena P., Pettirossi V., et al. The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. Haematologica 2009, 94:1307-1311.
28. Ilie M.I., Bence C., Hofman V., Long-Mira E., Butori C., et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann. Oncol. 2015, 26:238-244.
29. Cabillic F., Gros A., Dugay F., Begueret H., Mesturoux L., et al. Parallel FISH, and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J. Thorac. Oncol. 2014, 9:295-306.
30. Peled N., Palmer G., Hirsch F.R., Wynes M.W., Ilouze M., et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangemnet in a patient with metastatic non-small-cell lung cancer. J. Thorac. Oncol. 2012, 7:e14-e16.
31. Ren S., Hirsch F.R., Varella-Garcia M., Aisner D.L., Boyle T., et al. Atypical negative ALK break-apart FISH harboring a crizotinib-responsive ALK rearrangement in non-small-cell lung cancer. J. Thorac. Oncol. 2014, 9:e21-e23.
32. Pekar-Zlotin M., Hirsch F.R., Soussan-Gutman L., Ilouze M., Dvir A., et al. Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer. Oncologist 2015, 20:316-322.
33. Ilie M., Hofman P. Reply to the letter to the editor ALK FISH rearranged and amplified tumor with negative immunohistochemistry: a rare and challenging case concerning ALK status screening in lung cancer by Uguen et al. Ann. Oncol. 2015, 26:1802.
34. Thunnissen F.B., Ambergen A.W., Koss M., Travis W.D., O'Leary T.J., et al. Mitotic counting in surgical pathology: sampling bias, heterogeneity and statistical uncertainty. Histopathology 2001, 39:1-8.
35. Wolff A.C., Hammond M.E., Hicks D.G., Dowsett M., McShane L.M., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch. Pathol. Lab. Med. 2014, 138:241-256.
36. Savic S., Diebold J., Zimmermann A.K., Jochum W., Baschiera B., et al. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015, 89:104-109.
37. Sholl L.M., Weremowicz S., Gray S.W., Wong K.K., Chirieac L.R., et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J. Thorac. Oncol. 2013, 8:322-328.
38. Lindeman N.I., Cagle P.T., Beasley M.B., Chitale D.A., Dacic S., et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK Tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch. Pathol. Lab. Med. 2013, 137:828-860.
39. Blackhall F.H., Peters S., Bubendorf L., Dafni U., Kerr K.M., et al. Prevalence and clinical outcomes for patients with ALK-positive resected stage I to III adenocarcinoma: results from the European Thoracic Oncology Platform Lungscape Project. J. Clin. Oncol. 2014, 32:2780-2787.
40. Abe H., Kawahara A., Azuma K., Taira T., Takase Y., et al. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples. J. Thorac. Oncol. 2015, 10:800-805.